{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:03:41Z","timestamp":1762207421192,"version":"build-2065373602"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejim.2025.07.025","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:09:41Z","timestamp":1754737781000},"page":"106429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Management of asymptomatic patients with abnormal liver function tests"],"prefix":"10.1016","volume":"141","author":[{"given":"Stella","family":"Gabeta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-8464","authenticated-orcid":false,"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos K.","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.07.025_bib0001","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: evaluation of Abnormal Liver Chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2025.07.025_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1572-0241.2005.00341.x","article-title":"The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002","volume":"101","author":"Ioannou","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13250","article-title":"Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE)","volume":"13","author":"Donnan","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ejim.2025.07.025_bib0006","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global Epidemiology of Chronic Liver Disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.ejim.2025.07.025_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"S1","key":"10.1016\/j.ejim.2025.07.025_bib0011","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0168-8278(25)00314-9","article-title":"High prevalence of undiagnosed liver fibrosis in the adult European population driven by metabolic risk factors and alcohol consumption. results from the prospective liver screen cohort in 30,541 subjects","volume":"82","author":"Graupera","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(19)32908-3","article-title":"Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK","volume":"395","author":"Williams","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2025.07.025_bib0014","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(14)61838-9","article-title":"Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis","volume":"384","author":"Williams","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.025_bib0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(13)60355-4","article-title":"UK health performance: findings of the Global Burden of Disease Study 2010","volume":"381","author":"Murray","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.025_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2011.03.020","article-title":"Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort","volume":"56","author":"Armstrong","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0018","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000000233","article-title":"A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes","volume":"27","author":"Radcke","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0020","first-page":"623","article-title":"Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis","volume":"37","author":"Dalekos","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0021","first-page":"30","article-title":"What is the real function of the liver 'function' tests?","volume":"81","author":"Hall","year":"2012","journal-title":"Ulster Med J"},{"key":"10.1016\/j.ejim.2025.07.025_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0023","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: a 2021 Update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejim.2025.07.025_bib0024","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0025","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.20964","article-title":"Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women","volume":"42","author":"Prati","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cca.2021.12.026","article-title":"The ALT upper reference interval debate: blame it on the alcohol","volume":"526","author":"Vera","year":"2022","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.025_bib0027","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1373\/clinchem.2017.274977","article-title":"American liver guidelines and cutoffs for \"Normal\" ALT: a potential for overdiagnosis","volume":"63","author":"Panteghini","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejim.2025.07.025_bib0028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cld.742","article-title":"Misconception: you can't have liver disease with normal liver chemistries","volume":"12","author":"Lominadze","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.ejim.2025.07.025_bib0029","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJM197201272860407","article-title":"Alkaline phosphatase","volume":"286","author":"Kaplan","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0030","first-page":"1","article-title":"Structural, functional, and clinical aspects of gamma-glutamyltransferase","volume":"12","author":"Goldberg","year":"1980","journal-title":"CRC Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ejim.2025.07.025_bib0031","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0033","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0034","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2016.1217159","article-title":"Molecular diagnostic testing for primary biliary cholangitis","volume":"16","author":"Gatselis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejim.2025.07.025_bib0035","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1111\/j.1572-0241.2000.03293.x","article-title":"An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities","volume":"95","author":"Sorbi","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0036","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0037","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0038","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2025.07.025_bib0040","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2025.07.025_bib0041","article-title":"Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2025.07.025_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-238400","article-title":"Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed","volume":"13","author":"Dalekos","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ejim.2025.07.025_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.02.001","article-title":"NAFLD and autoimmune hepatitis: do not judge a book by its cover","volume":"75","author":"Dalekos","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2024.03.004","article-title":"Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasonography","volume":"125","author":"Santoro","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0046","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejim.2024.04.015","article-title":"Artificial intelligence supported ultrasonography: can it be the solution for early and accurate diagnosis of steatotic liver disease?","volume":"125","author":"Gabeta","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0047","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0048","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0049","article-title":"The application of artificial intelligence (AI)-based ultrasound for the diagnosis of fatty liver disease: a systematic review","volume":"15","author":"Nduma","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejim.2025.07.025_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0051","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0052","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0053","first-page":"431","article-title":"The changing epidemiology of hepatitis B in Greece","volume":"34","author":"Rigopoulou","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0054","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00042737-200509000-00005","article-title":"Intrafamilial spread of hepatitis B virus infection in Greece","volume":"17","author":"Zervou","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0055","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2025.07.025_bib0056","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2025.07.025_bib0057","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12352","article-title":"Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2","volume":"22","author":"Gane","year":"2015","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.025_bib0058","first-page":"321","article-title":"Aiming towards hepatitis C virus elimination in Greece","volume":"32","author":"Papatheodoridis","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0059","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hep.28943","article-title":"Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: a nationwide prospective cohort study","volume":"65","author":"Askgaard","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0061","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000517016","article-title":"Abnormal liver blood tests: primary care approach","volume":"40","author":"Mijac","year":"2022","journal-title":"Dig Dis"},{"key":"10.1016\/j.ejim.2025.07.025_bib0062","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2013II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.ejim.2025.07.025_bib0063","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.ejim.2025.07.025_bib0064","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/BF01324898","article-title":"The SGOT\/SGPT ratio\u2013an indicator of alcoholic liver disease","volume":"24","author":"Cohen","year":"1979","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejim.2025.07.025_bib0065","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1053\/j.gastro.2006.08.020","article-title":"Utility of a new model to diagnose an alcohol basis for steatohepatitis","volume":"131","author":"Dunn","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0066","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the american association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib132","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders. Report of an international consensus meeting","volume":"11","author":"Benichou","year":"1990","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0069","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/flgastro-2021-101886","article-title":"Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)","volume":"13","author":"Brennan","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ajg.2010.102","article-title":"The myth of statin-induced hepatotoxicity","volume":"105","author":"Bader","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0067","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0068","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0071","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.025_bib0072","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12109","article-title":"Review article: herbal and dietary supplement hepatotoxicity","volume":"37","author":"Bunchorntavakul","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2025.07.025_bib0073","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in Drug and Herb Induced Liver Injury: the Update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.07.025_bib0074","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0075","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1136\/jim-2021-002206","article-title":"Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis","volume":"70","author":"Cheema","year":"2022","journal-title":"J Investig Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.025_bib0076","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","article-title":"Busting the myth of methotrexate chronic hepatotoxicity","volume":"19","author":"Di Martino","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0077","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/liv.14480","article-title":"Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study","volume":"40","author":"Gronbaek","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0078","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","article-title":"Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis","volume":"19","author":"Lamba","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102280","article-title":"Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis","volume":"65","author":"Hahn","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejim.2025.07.025_bib0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41424-018-0028-1","article-title":"Role of age in presentation, response to therapy and outcome of autoimmune hepatitis","volume":"9","author":"Baven-Pronk","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0081","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/liv.14900","article-title":"Autoimmune hepatitis in patients aged 70 years or older: disease characteristics, treatment response and outcome","volume":"41","author":"Dalekos","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0082","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jped.2018.04.007","article-title":"Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes","volume":"95","author":"Porta","year":"2019","journal-title":"J Pediatr (Rio J)"},{"journal-title":"J Hepatol","article-title":"EASL Clinical Practice Guidelines on the management of autoimmune hepatitis","year":"2025","key":"10.1016\/j.ejim.2025.07.025_bib0083"},{"key":"10.1016\/j.ejim.2025.07.025_bib0084","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v21.i1.60","article-title":"Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics","volume":"21","author":"Gatselis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0085","article-title":"Recent advances in the diagnosis and management of autoimmune hepatitis","volume":"132","author":"Dalekos","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0086","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2023.06.002","article-title":"Autoimmune hepatitis: epidemiology, subtypes, and presentation","volume":"28","author":"Shiffman","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ejim.2025.07.025_bib0088","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5114\/ceh.2020.93051","article-title":"Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly","volume":"6","author":"Sonthalia","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0089","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/hepr.13342","article-title":"Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ejim.2025.07.025_bib0090","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/MEG.0000000000000424","article-title":"Autoimmune liver disease and concomitant extrahepatic autoimmune disease","volume":"27","author":"Muratori","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0091","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/liv.13236","article-title":"Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0092","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clinre.2018.12.002","article-title":"Autoimmune hepatitis in patients with multiple sclerosis: the role of immunomodulatory treatment","volume":"43","author":"Rigopoulou","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0093","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/liv.15382","article-title":"Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality","volume":"42","author":"Birn-Rydder","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0094","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0095","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","article-title":"Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing","volume":"74","author":"Galaski","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0096","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0097","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2022.11.013","article-title":"Autoimmune serology testing in clinical practice: an updated roadmap for the diagnosis of autoimmune hepatitis","volume":"108","author":"Dalekos","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0098","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0953-6205(02)00089-4","article-title":"Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview","volume":"13","author":"Dalekos","year":"2002","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0099","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.03.033","article-title":"EASL Clinical Practice Guidelines on haemochromatosis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0100","first-page":"932","article-title":"Secondary iron overload and the liver: a comprehensive review","volume":"11","author":"Pinyopornpanish","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0101","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.GIM.0000096500.66084.85","article-title":"Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing","volume":"5","author":"Palomaki","year":"2003","journal-title":"Genet Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0102","doi-asserted-by":"crossref","first-page":"k5222","DOI":"10.1136\/bmj.k5222","article-title":"Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank","volume":"364","author":"Pilling","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2025.07.025_bib0103","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/MEG.0000000000001670","article-title":"Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from two tertiary Greek centers","volume":"32","author":"Tampaki","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0104","article-title":"A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on wilson disease from the American association for the study of liver diseases","author":"Schilsky","year":"2022","journal-title":"Hepatology"},{"journal-title":"J Hepatol","article-title":"EASL-ERN clinical practice guidelines on Wilson's disease","year":"2025","key":"10.1016\/j.ejim.2025.07.025_bib0105"},{"key":"10.1016\/j.ejim.2025.07.025_bib0106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","article-title":"Diagnosis and phenotypic classification of Wilson disease","volume":"23","author":"Ferenci","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2025.07.025_bib0107","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/cen.13312","article-title":"Incidence of abnormal liver biochemical tests in hyperthyroidism","volume":"86","author":"Lin","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.025_bib0108","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/jcm12010310","article-title":"Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes","volume":"12","author":"Han","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","article-title":"American college of gastroenterology guidelines update: diagnosis and management of celiac disease","volume":"118","author":"Rubio-Tapia","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ajg.2015.192","article-title":"Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population","volume":"110","author":"Castillo","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0111","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ejim.2025.07.025_bib0112","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0113","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2017.05.006","article-title":"Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece","volume":"42","author":"Gatselis","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2478\/jtim-2023-0098","article-title":"Total and individual PBC-40 scores are reliable for the assessment of health-related quality of life in Greek patients with primary biliary cholangitis","volume":"11","author":"Rigopoulou E","year":"2023","journal-title":"J Transl Intern Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0116","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0117","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0118","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2025.07.025_bib0119","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","article-title":"Factors associated with progression and outcomes of early stage primary biliary cholangitis","volume":"18","author":"Gatselis","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2025.07.025_bib0122","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0123","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0124","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"Hov","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0125","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.025_bib0126","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00005-019-00550-9","article-title":"Variant and specific forms of autoimmune cholestatic liver diseases","volume":"67","author":"Dalekos","year":"2019","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.ejim.2025.07.025_bib0127","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha1-Antitrypsin Deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.07.025_bib0128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","article-title":"EASL clinical practice guidelines on genetic cholestatic liver diseases","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2025.07.025_bib0129","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/apt.16118","article-title":"Review article: liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1","volume":"52","author":"Nayagam","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2025.07.025_bib0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(24)02351-1","article-title":"Pregnancy and the liver","volume":"405","author":"Rahim","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.07.025_bib0131","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2023.03.006","article-title":"EASL clinical practice guidelines on the management of liver diseases in pregnancy","volume":"79","year":"2023","journal-title":"J Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:59:17Z","timestamp":1762207157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":131,"alternative-id":["S0953620525003085"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.025","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of asymptomatic patients with abnormal liver function tests","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106429"}}